002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis — Christopher Em Griffiths (2017) | RDL Network
002 Switching treatments of etanercept biosimilar GP2015 with originator product does not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis
Andrew Blauvelt, Kim Papp, Christopher Em Griffiths, L. Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin
Alexander Egeberg, Joseph F. Merola, Knut Schäkel, L. Puig, Patrick Mahar, Isabella Yali Wang, Imre Pávó, Christopher Schuster, Christopher Em Griffiths
Alexander Egeberg, Joseph F. Merola, Knut Schäkel, L. Puig, Patrick Mahar, Isabella Yali Wang, Imre Pávó, Christopher Schuster, Christopher Em Griffiths
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.